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Early changes in plasma DNA 
levels of mutant KRAS as a 
sensitive marker of response to 
chemotherapy in pancreatic cancer
Marzia Del Re1, Caterina Vivaldi2, Eleonora Rofi1, Enrico Vasile2, Mario Miccoli3, Chiara 
Caparello2, Paolo Davide d’Arienzo2,4, Lorenzo Fornaro2, Alfredo Falcone2 & Romano Danesi1
Pancreatic cancer (PDAC) is still lacking of reliable markers to monitor tumor response. CA 19-9 is the 
only biomarker approved, despite it has several limitations in sensitivity and specificity. Since mutations 
of KRAS occur in more than 90% of tumors, its detection in circulating free tumor DNA (cftDNA) could 
represent a biomarker to monitor chemotherapy response. Twenty-seven advanced PDAC patients 
given first-line 5-fluorouracil, irinotecan and oxaliplatin or gemcitabine and nab-paclitaxel were 
enrolled. Three ml of plasma were collected: 1) before starting chemotherapy (baseline); 2) at day 15 of 
treatment; and 3) at each clinical follow-up. cftDNA was extracted and analysed for KRAS mutations 
(mutKRAS) by digital droplet PCR. Nineteen patients displayed a mutKRAS in baseline plasma samples. 
There was a statistically significant difference in progression-free survival (PFS) and overall survival (OS) 
in patients with increase vs. stability/reduction of cftDNA in the sample collected at day 15 (median 
PFS 2.5 vs 7.5 months, p = 0.03; median OS 6.5 vs 11.5 months, p = 0.009). The results of this study 
demonstrate that cftDNA mutKRAS changes are associated with tumor response to chemotherapy and 
support the evidence that mutKRAS in plasma may be used as a new marker for monitoring treatment 
outcome and disease progression in PDAC.
Pancreatic adenocarcinoma (PDAC) represents the fourth leading cause of cancer-related deaths in Western 
countries and only 10–20% of patients are diagnosed with a resectable disease1. Chemotherapy represents 
the milestone of treatment of advanced disease; indeed, among the combinations developed in recent years, 
5-fluorouracil, irinotecan and oxaliplatin (FOLFIRINOX), and the association of gemcitabine and nab-paclitaxel 
(GEMnPAC) have demonstrated improved survival and represent now the standard of care in first-line treat-
ment2, 3.
However, since pancreatic tumor tissue is surrounded by a dense fibrotic stroma, the evaluation of tumor 
response to therapy is particularly challenging and imaging techniques do not always provide an accurate esti-
mate, despite the significant costs4, 5. For this reason, the monitoring of these tumors by blood markers is a valu-
able alternative and is based on the evaluation of the Carbohydrate Antigen 19-9 (CA 19-9) levels, the standard 
serum marker for pancreatic cancer. Although CA 19-9 has been approved to monitor tumor response, it has 
several limitations including: (1) low sensitivity and specificity (estimated to be around 79% and 82%, respec-
tively); (2) occurrence of unspecific changes in serum samples; (3) poor accuracy in the identification of small 
tumors6, 7. These issues limit the utility of CA 19-9 as a biomarker and highlight the need for new biomarkers to 
complement the imaging in order to obtain a more effective monitoring of these patients and improve the clinical 
outcome. Alternative approaches for PDAC monitoring are represented by circulating tumor cells (CTCs), which 
may predict poor disease outcome8, though their use is limited by false negative tests and high costs.
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The majority of pancreatic cancers (from 75 to 95%) harbor a KRAS mutation at codon 129 and a significant 
difference in survival was observed in patients with detectable or undetectable KRAS mutations (mutKRAS) in cir-
culating free tumor DNA (cftDNA)10. Moreover, the presence of mutKRAS in plasma samples after surgical resec-
tion of PDAC has been associated with poor survival11, 12. In addition, looking at the specific type of mutation, 
the presence of KRAS p.G12V seems to be associated with a decrease in survival of pancreatic cancer patients13.
Tissue availability is recognized as a crucial issue, as there are several limitations to obtain repeated biopsies 
(i.e. invasiveness) and to capture tumor heterogeneity due to the practical constraints to collect multiple samples. 
In contrast, the detection of somatic mutations in cftDNA released in plasma from apoptotic and necrotic tumor 
cells both from primary tumor and metastatic lesions is feasible and affordable in terms of costs14. Thus, cftDNA 
may reflect the tumor burden in cancer patients and is a valuable option for a better monitoring of response; it 
may complement imaging in order to obtain a more effective management of patients, identify early resistance 
and improve clinical outcome15.
Therefore, the aim of the present study was to monitor the allelic burden of mutKRAS in patients with advanced 
PDAC undergoing first-line combination chemotherapy. In particular, the correlation between early variations of 
cftDNA mutKRAS after 15 days of treatment with response to therapy was explored, in order to provide an effective 
tool to predict the effectiveness of therapy early after its beginning.
Results
Study population. A total of 27 patients with locally advanced (n = 4; 15%) and metastatic (n = 23; 85%) 
PDAC were included in this biomarker study (Table 1). Median age was 68 years (range 49–77).
At a median follow up of 7.6 months, 13 patients (54%) underwent disease progression and 6 (22%) died. 
Median progression-free survival (PFS) and overall survival (OS) were 7.4 and 11.5 months, respectively. 
Response rate was 38% and disease control rate (DCR) defined as the sum of partial response (PR) and stable 
disease (SD) was 73%.
Analysis of mutKRAS cftDNA at baseline. At baseline, 19 out of 27 patients (70.4%) were carriers of one 






















Normal (0–37 U/ml) 7 (26%)
Abnormal (<59 ULN) 11 (41%)
Abnormal (≥59 ULN) 9 (33%)
Baseline KRAS cftDNA status







Median baseline mutKRAS (copies/ml, 
range) 2100 (80–64800)
Table 1. Characteristics of patients.
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another the p.G13D. In mutKRAS patients, the amount of cftDNA ranged from 80 to 64800 copies/ml (Table 1). 
Eight patients were negative for cftDNA mutKRAS at baseline (3 patients were stage III and 5 were stage IV); one of 
them turned to positivity at day 15 and another one at the first radiological evaluation (2 months after treatment 
start). There was no statistically significant difference in mutKRAS cftDNA positivity at baseline in patients with 
metastatic vs. locally advanced disease (p = 0.065). Besides, there was no statistically significant difference in 
mutKRAS positivity by stratifying patients by gender (p = 0.103), age (p = 0.087), performance status (PS) (p = 1), 
disease site (p = 0.103), and stage (p = 0.065).
No statistically significant differences in median PFS and OS in patients with baseline positive or nega-
tive cftDNA mutKRAS were found (PFS: 7.4 months vs. not reached, p = 0.24; OS: 11.5 months vs. not reached, 
p = 0.16; Table 2).
On the contrary, there was a statistically significant difference between cftDNA mutKRAS positivity at baseline 
and the presence of liver metastasis (p = 0.008) or abnormal CA 19-9 levels (p = 0.011).
Monitoring mutKRAS cftDNA during treatment and correlation with outcome. Twenty-five out of 
27 patients (17 positive cftDNA mutKRAS and 8 wild type) had more than one blood sample drawn. One patient 
died within a month of study entry and another one withdrew the consent to participate in the study.
There was a statistically significant difference in PFS between patients displaying an increase vs. stability/
reduction of mutKRAS cftDNA at the 15 day-sample (median PFS 2.5 vs. 7.5 months, p = 0.03, Fig. 1). In particular, 
according to the radiological evaluation 2 months after the beginning of treatment, all patients displaying cftDNA 
increase at the 15th day (3 baseline mutKRAS and 1 wild type that became mutKRAS) had disease progression.
Interestingly, a statistically significant difference was also observed in median OS (6.5 vs. 11.5 months, 
p = 0.009) in patients displaying an increase vs. reduction of mutKRAS cftDNA, respectively. None of the other 
parameters (sex, age, stage, PS, primary tumor location, baseline CA 19-9) was significantly correlated with PFS 
and/or OS (Table 2).
The early mutKRAS cftDNA variation did not correlate with tumor response (Fisher’s exact test p = 0.09; 
Mann-Whitney test p = 0.156) even if a trend toward better DCR in patients with early mutKRAS cftDNA decrease 
was found (Fisher’s exact test p = 0.08; Mann-Whitney test p = 0.059, Fig. 2).
Noteworthy, the comparison of mutKRAS cftDNA changes in samples taken at baseline and after 2 months 
(at the time of first radiological evaluation) demonstrated that median PFS was 7.5 months for patients whose 
cftDNA mutKRAS decreased vs 2.8 months of subjects with increasing cftDNA mutKRAS levels (p = 0.028). Figure 3 
reports the results of 3 representative patients as an example of PR (Fig. 3a), early PD (Fig. 3b) and early disease 
response followed by progression (Fig. 3c), while on the other hand, Fig. 4 reports the same patients comparing 
the cftDNA mutKRAS to the CA 19-9 monitoring.
Discussion
The present study provides the evidence that the change of mutKRAS cftDNA levels between baseline vs. day 15 is 
an early predictor of clinical outcome. To the best of our knowledge, the present study shows for the first time that 
cftDNA mutKRAS variation is an early marker of response to treatment in PDAC. In our pilot study, all patients 
PFS OS
Months (median) p Months (median) p
Age
<Median vs. ≥Median 7.4 vs. 8.5 0.38 NR vs.11.5 0.42
Gender
Male vs. Female 7.5 vs. 7.3 0.65 11.5 vs. NR 0.35
Stage
III vs. IV 7.4 vs. 7.3 0.36 NR vs. 11.5 0.4
ECOG Performance Status
0 vs. 1 7.5 vs. 2.8 0.32 11.5 vs. 8.5 0.06
Primary tumor location
Head vs Body-tail 7.4 vs. 7.5 0.92 NR vs. 11.5 0.55
Baseline CA 19-9
Normal vs. Abnormal (<59 ULN vs. Abnormal (≥59 ULN) NR vs. 7.3 vs. 2.8 0.06 NR vs. NR vs. 11.5 0.28
Liver metastases
Yes vs. No 7.2 vs. 8.5 0.37 11.5 vs. NR 0.51
Chemotherapy regimen
FOLFIRINOX vs. GEMnPAC 7.4 vs. 7.5 0.99 NR vs. 11.5 0.4
cftDNA detectable
Yes vs. No 7.4 vs. NR 0.24 11.5 vs. NR 0.16
Early mutKRAS cftDNA variation
Increase vs. No increase 2.5 vs. 7.5 0.03 6.5 vs. 11.5 0.009
Table 2. Univariate analysis for the correlation of PFS and OS with clinical status of patients. ULN: upper limit 
of normality.
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having an early increase in cftDNA mutKRAS underwent rapid disease progression, supporting the hypothesis that 
cftDNA mutKRAS changes are associated with tumor dynamics. Experimental evidences demonstrate that cftDNA 
is a valuable biomarker to predict the response or resistance to treatment not only with targeted therapies, but also 
with chemotherapy16.
While previous studies demonstrated that pancreatic cancer patients with detectable mutKRAS cftDNA before 
or after initiation of chemotherapy have a shorter survival time13, 17, 18, our results did not find a statistically sig-
nificant difference in median PFS and OS in patients with baseline positive or negative mutKRAS cftDNA (median 
PFS 7.4 months vs. not reached, p = 0.24; median OS 11.5 months vs. not reached, p = 0.16, respectively). Despite 
enrolling also patients with locally advanced disease, we did not find any difference between mutKRAS cftDNA 
positivity in locally advanced vs. metastatic patients. The lack of difference in OS between mutKRAS cftDNA 
positive and negative patients could be explained by the relatively low number of survival events - at the time of 
analysis 22% of the patients were deceased - and by differences in the cftDNA mutKRAS detection method used 
in our study. Of note, the technique used in the present study is characterized by a high sensitivity, as it is able to 
detect small amounts of cftDNA (median baseline KRAS copies/ml: 2100; range: 80–64800 copies/ml). In fact, 
in the present study, 70.4% of patients had detectable mutKRAS cftDNA prior to treatment, whereas in previously 
published studies detectability ranged from 0% to 62.2%13, 17–20. This high positivity rate may be dependent on the 
sensitivity of the method used for the analysis being digital droplet PCR (ddPCR) the most sensitive compared 
to other techniques.
Two out of 6 mutKRAS cftDNA negative patients became positive during treatment, one after 15 days and 
another after 8 weeks, respectively. It is unclear if this is simply due to one or more of the following reasons: (1) 
increase in tumor burden; (2) molecular heterogeneity within the primary tumor; (3) changes in dynamics of 
mutKRAS cftDNA released from cells; or (4) the emergence of metastases or CTCs with different molecular clones 
contributing to the cftDNA pool released. It would be extremely interesting, in the future, to analyze tumor biop-
sies from these patients to confirm the proportion of mutKRAS.
Figure 1. PFS according to early mutKRAS cftDNA variation (increase vs. reduction).
Figure 2. Plot showing early mutKRAS cftDNA variations (% change in number of copies) in patients with PR or 
SD vs. PD.
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Figure 3. Representative ddPCR plots showing mutKRAS cftDNA variations during follow up of patients. The 
mutKRAS cftDNA are the blue dots circled in red. Upper panel: metastatic patient who developed PR to first-line 
FOLFIRINOX. (1) Baseline detection of KRAS p.G12D (11600 copies/ml); (2) p.G12D declined after 15 days 
(900 copies/ml); (3) p.G12D still reduced after 2 months (130 copies/ml); (4) pG12D is undetectable after 7 
months of chemotherapy (0 copies/ml). Middle panel: patient with local recurrence who developed early PD 
during first-line FOLFIRINOX. (1) Baseline detection of KRAS p.G12D (240 copies/ml); (2) slight increase 
of p.G12D (245 copies/ml) after 15 days; (3) p.G12D increase (2700 copies/ml) after 2 months. This patient 
died due to PD two weeks after radiological re-evaluation at 2 months. Lower panel: metastatic patient who 
developed PR and subsequent early PD to GEMnPAC. (1) Baseline detection of KRAS p.G12D (3200 copies/
ml); (2) undetectable cftDNA at day 15 (0 copies/ml); (3) increase of p.G12D (900 copies/ml) after 2 months; 
(4) further increase of p.G12D (2800 copies/ml) corresponding to radiologically-confirmed PD at 4 months. 
Clinical condition progressively deteriorated and patients died because of PD 5 months after diagnosis.
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The present study was aimed to explore whether early changes in cftDNA levels might be useful to monitor 
treatment response. We observed a trend towards better DCR in patients with early mutKRAS cftDNA decrease 
during treatment. Recently, an article on this topic has been published10, demonstrating that changes in cftDNA 
levels were related to the radiological response. However, our study has been conducted on a larger and more 
homogeneous cohort of patients, treated with improved first-line combination regimens, and investigated the role 
of early variations mutKRAS cftDNA, at variance with other publications in the field.
Under this point of view, future studies should focus on this issue also by comparing paired tumor biopsies 
and plasma from these patients, to confirm the correlation between mutKRAS cftDNA and treatment outcome. 
Indeed, the use of cftDNA approach and of a sensitive method, such as ddPCR, allow the detection of very small 
amounts of mutated clones in a large background of wild type DNA, minimizing the false negative data. In this 
context, monitoring the amount or the appearance of tumor molecular alterations (i.e. KRAS or other mutations 
like TP53, SMAD4) in cftDNA during treatment is a promising and reliable tool to monitor treatment resistance 
or response, as it reflects the tumor dynamics and tissue heterogeneity. In conclusion, although the present study 
examines a small cohort of patients, the results are in support of the hypothesis that cftDNA may be used as a 
new marker to monitor treatment outcome and disease progression in PDAC potentially earlier than radiological 
findings, suggesting that cftDNA mutKRAS changes are associated with tumor dynamics.
Patients and Methods
Patients. The study enrolled 27 consecutive patients with histologically proven advanced PDAC undergoing 
first-line chemotherapy with FOLFIRINOX or GEMnPAC as per standard practice. Patients were accrued from 
November 2015 to December 2016 at the Medical Oncology Unit of the University Hospital of Pisa. Treatment 
Figure 4. Changes in cftDNA mutKRAS levels compred to CA 19-9 in a case of early PD (upper panel), PR 
(middle panel) and early PR followed by PD (lower panel).
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was administered until PD, unacceptable toxicity or patient refusal. Patients underwent standard disease eval-
uation by imaging according to RECIST 1.1 criteria: computed tomography (CT) of abdomen and chest was 
performed at baseline and every 8 weeks until PD. Disease control rate (DCR) was estimated as the percentage of 
patients who have achieved PR and SD during treatment. CA 19-9 was determined at every radiological evalua-
tion. Data on PS, adverse events, serum chemistry, hematology and concomitant medications were collected at 
every chemotherapy cycle in a prospective database. Blood samples were drawn by venous puncture as follows: 
(1) baseline (immediately before chemotherapy administration); (2) after 15 days (before the second cycle of 
FOLFIRINOX or on day 15 of cycle 1 of GEMnPAC); and (3) at first radiological evaluation.
The study was approved by the Ethics Committee of Pisa University Hospital and conducted in accordance to 
the principles of the Declaration of Helsinki; all patients gave their signed informed consent before blood collec-
tion and cftDNA analysis.
Plasma collection, cftDNA extraction and KRAS analysis. Six ml of blood were collected in tubes 
containing EDTA and centrifuged at 3000 rpm for 10 min at 4 °C within 2 hours after blood drawing; plasma 
samples were stored at −80 °C until analysis. cftDNA was extracted using a QIAamp Circulating nucleic acid kit 
(Qiagen®, Valencia, CA, USA) from 3 ml of plasma following the manufacturer’s protocol and cftDNA was eluted 
with 50 μl of elution buffer.
The analysis was performed with a ddPCR KRAS Screening Multiplex Kit (BioRad®, Hercules, CA) and 
the results were confirmed using single mutation assays (BioRad®, Hercules, CA) to detect p.G12D, p.G12V, 
p.G12R, p.G13D. Based on the information reported in the technical annex, the MiQE Context Sequence is 
ATTATTTTTATTATAAGGCCTGCTGAAAATGACTGAATATAAACTTGTGGTAGTTGGAGCT[G/C]
GTGGCGTAGGCAAGAGTGCCTTGACGATACAGCTAATTCAGAATCATTTTGTGGACGAATA (Entrez 
Gene ID 3845, RefSeq accessions NM_004985, NM_033360; Ensemble Accessions ENST00000311936, 
ENST00000256078, ENST00000556131, ENST00000557334).
Briefly, PCR reactions were assembled as per manufacturer instruction and the amplification protocol was 
standardized for all mutations to the following conditions: 95 °C × 10 min, 94 °C × 30 s and 55 °C × 60 s (35 
cycles), 98 °C × 10 min, and 4 °C hold. As a positive control for mutKRAS, the cftDNA from 30 patients with known 
mutKRAS colorectal cancer was used, while the DNA extracted from plasma of 43 healthy blood donors was used 
as negative control. The droplet-reader was used for fluorescence signal quantification; the QuantaSoft (BioRad®, 
Hercules, CA) software measured the number of positive vs. negative droplets for both fluorophores (FAM/HEX) 
and their ratio was fitted to a Poisson distribution to determine the copy number/ml of the target molecule in 
the input reaction. A fluorescence intensity threshold of 3000 was set as a cut-off point and all droplets above 
this threshold were scored as positive for mutKRAS. The sample was considered as KRAS positive when at least 3 
positive HEX droplets were identified above the threshold level.
Statistical analyses. OS was measured from the date of the first cycle of chemotherapy to death or last 
follow-up visit. PFS was measured from the date of the first cycle of chemotherapy to disease progression or death, 
whichever occurred first. PFS and OS were estimated using the Kaplan-Meier product-limit method. Shapiro-Wilk 
test was performed to verify normality of distributions of cftDNA mutKRAS variations; the latter were corre-
lated with tumor response by Mann-Whitney test and Fisher’s exact test and with OS and PFS by log-rank test. 
Significance was set at p < 0.05 for two-tailed tests. Characteristics of patients, including and KRAS status and CA 
19-9, were compared by the Fisher’s exact test. Univariate analysis was performed to correlate PFS and OS with 
demographics and clinical status of patients, i.e., ECOG PS, stage of disease, primary tumor location, chemother-
apy regimen, site of disease, liver metastases, CA 19-9 levels and mutKRAS. Cut-off data of the analyses was January 
2017. The cftDNA mutKRAS variation was evaluated both as a categorical variable (increase vs. no increase) and 
as a continuous variable considered as the percentage decreasing with respect to the baseline amount. Statistical 
analyses were carried out using the statistical software package SPSS 19.0 (SPSS, Chicago, IL, USA).
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